journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care

journal
https://www.readbyqxmd.com/read/28224308/a-methodological-proposal-to-evaluate-the-cost-of-duration-moral-hazard-in-workplace-accident-insurance
#1
Ángel Martín-Román, Alfonso Moral
The cost of duration moral hazard in workplace accident insurance has been amply explored by North-American scholars. Given the current context of financial constraints in public accounts, and particularly in the Social Security system, we feel that the issue merits inquiry in the case of Spain. The present research posits a methodological proposal using the econometric technique of stochastic frontiers, which allows us to break down the duration of work-related leave into what we term "economic days" and "medical days"...
February 21, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28197784/corruption-costs-lives-evidence-from-a-cross-country-study
#2
Qiang Li, Lian An, Jing Xu, Mina Baliamoune-Lutz
This paper investigates the effect of corruption on health outcomes by using cross-country panel data covering about 150 countries for the period of 1995 to 2012. We employ ordinary least squares (OLS), fixed-effects and two-stage least squares (2SLS) estimation methods, and find that corruption significantly increases mortality rates, and reduces life expectancy and immunization rates. The results are consistent across different regions, gender, and measures of corruption. The findings suggest that reducing corruption can be an effective method to improve health outcomes...
February 14, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28194534/the-impact-of-physician-level-drug-budgets-on-prescribing-behavior
#3
Katharina Elisabeth Fischer, Taika Koch, Karel Kostev, Tom Stargardt
To contain pharmaceutical spending, drug budgets have been introduced across health systems. Apart from analyzing whether drug budgets fulfill their overall goal of reducing spending, changes in the cost and quality of prescribing and the enforcement mechanisms put in place need evaluation to assess the effectiveness of drug budgets at the physician level. In this study, we aim to analyze the cost and quality of prescribing conditional on the level of utilization of the drug budget and in view of varying levels of enforcement in cases of overspending...
February 13, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28190188/the-economic-burden-of-diabetes-to-french-national-health-insurance-a-new-cost-of-illness-method-based-on-a-combined-medicalized-and-incremental-approach
#4
Grégoire de Lagasnerie, Anne-Sophie Aguadé, Pierre Denis, Anne Fagot-Campagna, Christelle Gastaldi-Menager
A better understanding of the economic burden of diabetes constitutes a major public health challenge in order to design new ways to curb diabetes health care expenditure. The aim of this study was to develop a new cost-of-illness method in order to assess the specific and nonspecific costs of diabetes from a public payer perspective. Using medical and administrative data from the major French national health insurance system covering about 59 million individuals in 2012, we identified people with diabetes and then estimated the economic burden of diabetes...
February 11, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28185028/improving-risk-equalization-using-information-on-physiotherapy-diagnoses
#5
Frank Eijkenaar, René C J A van Vliet
BACKGROUND: Worldwide, risk-equalization (RE) models in competitive health insurance markets have evolved from simple demographic models to sophisticated models containing diagnosis and pharmacy-based indicators of health. However, these models still have important imperfections; adding information on (diagnoses of) physiotherapy treatment may further improve RE-models. Therefore, a new risk-adjuster based on physiotherapy costs in the prior year was introduced in the Dutch RE-model of 2016...
February 9, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28180977/a-methodological-framework-for-assessing-agreement-between-cost-effectiveness-outcomes-estimated-using-alternative-sources-of-data-on-treatment-costs-and-effects-for-trial-based-economic-evaluations
#6
Felix Achana, Stavros Petrou, Kamran Khan, Amadou Gaye, Neena Modi
A new methodological framework for assessing agreement between cost-effectiveness endpoints generated using alternative sources of data on treatment costs and effects for trial-based economic evaluations is proposed. The framework can be used to validate cost-effectiveness endpoints generated from routine data sources when comparable data is available directly from trial case report forms or from another source. We illustrate application of the framework using data from a recent trial-based economic evaluation of the probiotic Bifidobacterium breve strain BBG administered to babies less than 31 weeks of gestation...
February 9, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28160100/healthcare-utilization-and-costs-in-primary-care-patients-with-dementia-baseline-results-of-the-delphi-trial
#7
Bernhard Michalowsky, Steffen Flessa, Tilly Eichler, Johannes Hertel, Adina Dreier, Ina Zwingmann, Diana Wucherer, Henriette Rau, Jochen René Thyrian, Wolfgang Hoffmann
The objectives of this cross-sectional analysis were to determine healthcare resource utilization and cost for community-dwelling patients with dementia (PWD) from a payer's and societal perspective, and to analyze the associations between costs and sociodemographic and clinical variables. Analysis of healthcare costs from a payer's perspective was based on a sample of 425 PWD, analysis of healthcare costs from societal perspective on a subsample of 254 PWD and their informal caregivers. Frequency of healthcare resource utilization was assessed by means of questionnaires...
February 3, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28144758/a-healthy-immigrant-effect-or-a-sick-immigrant-effect-selection-and-policies-matter
#8
Amelie F Constant, Teresa García-Muñoz, Shoshana Neuman, Tzahi Neuman
Previous literature on a variety of countries has documented a "healthy immigrant effect" (HIE). Accordingly, immigrants arriving in the host country are, on average, healthier than comparable natives. However, their health status dissipates with additional years in the country. HIE is explained through the positive self-selection of healthy immigrants as well as the positive selection, screening and discrimination applied by host countries. In this article we study the health trajectories of immigrants within the context of selection and migration policies...
January 31, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28093662/a-cost-effectiveness-analysis-of-lisdexamfetamine-dimesylate-in-the-treatment-of-adults-with-attention-deficit-hyperactivity-disorder-in-the-uk
#9
Evelina A Zimovetz, Alain Joseph, Rajeev Ayyagari, Josephine A Mauskopf
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a chronic neurobehavioral disorder in children that may persist into adulthood. Lisdexamfetamine dimesylate (LDX) is approved in many countries for ADHD treatment in children, adolescents, and adults. OBJECTIVES: Estimate the cost-effectiveness of LDX as a first- or second-line treatment for adults with ADHD from the United Kingdom (UK) National Health Service (NHS) perspective compared with methylphenidate extended release (MPH-ER) and atomoxetine (ATX)...
January 16, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28091762/good-jobs-good-pay-better-health-the-effects-of-job-quality-on-health-among-older-european-workers
#10
Golo Henseke
Using data from the Survey of Health, Ageing and Retirement in Europe, this study presents new evidence on the effects of job quality on the occurrence of severe acute conditions, the level of cardiovascular risk factors, musculoskeletal disorders, mental health, functional disabilities and self-assessed health among workers aged 50+. By combining intrinsic job quality with job insecurity and pay the study maps out multiple potential pathways through which work may affect health and well-being. Levering longitudinal data and external information on early retirement ages allows for accounting of unobserved heterogeneity, selection bias and reverse causality...
January 13, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28064379/investigating-social-inequalities-in-older-adults-dentition-and-the-role-of-dental-service-use-in-14-european-countries
#11
Jing Shen, Stefan Listl
BACKGROUND: Oral disease, despite being largely preventable, remains the most common chronic disease worldwide and has a significant negative impact on quality of life, particularly among older adults. OBJECTIVE: This study is the first to comprehensively and at a large scale (14 European countries) measure the social inequalities in the number of natural teeth (an informative oral health marker) in the over 50-year-old population and to investigate the extent to which such inequalities are attributable to dental service use...
January 7, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28050682/competition-and-quality-indicators-in-the-health-care-sector-empirical-evidence-from-the-dutch-hospital-sector
#12
R R Croes, Y J F M Krabbe-Alkemade, M C Mikkers
There is much debate about the effect of competition in healthcare and especially the effect of competition on the quality of healthcare, although empirical evidence on this subject is mixed. The Netherlands provides an interesting case in this debate. The Dutch system could be characterized as a system involving managed competition and mandatory healthcare insurance. Information about the quality of care provided by hospitals has been publicly available since 2008. In this paper, we evaluate the relationship between quality scores for three diagnosis groups and the market power indicators of hospitals...
January 3, 2017: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28028622/market-approval-for-drugs-in-the-eu-time-to-change-direction
#13
EDITORIAL
Alessandro Curto, Katelijne van de Vooren, Livio Garattini
No abstract text is available yet for this article.
December 27, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28008547/gender-specific-practice-styles-and-ambulatory-health-care-expenditures
#14
Boris Kaiser
This paper explores the role of physician gender in the expenditures for ambulatory care as a potential source of practice style variation. We exploit a large doctor-patient panel dataset based on insurance-claims data from Switzerland to estimate the effect of physician gender on health care expenditures. We find considerable heterogeneity across specialties. In primary care, female doctors are found to produce similar overall expenditures per visit as their male colleagues, but significantly smaller prescribing costs and significantly higher laboratory costs...
December 22, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/28008546/cost-effectiveness-analysis-of-the-use-of-daclatasvir%C3%A2-%C3%A2-sofosbuvir%C3%A2-%C3%A2-ribavirin-16%C3%A2-weeks-and-12%C3%A2-weeks-vs-sofosbuvir%C3%A2-%C3%A2-ribavirin-16%C3%A2-weeks-and-24%C3%A2-weeks-for-the-treatment-of-cirrhotic-patients-affected-with-hepatitis-c-virus-genotype-3-in-italy
#15
Umberto Restelli, Alfredo Alberti, Adriano Lazzarin, Marzia Bonfanti, Carmela Nappi, Davide Croce
The WHO estimates that more than 185 million people are infected with hepatitis C virus (HCV) worldwide. The aim of the study is to assess the incremental cost-effectiveness ratio (ICER) of the use of daclatasvir (DCV) + sofosbuvir (SOF) + ribavirin (RBV) for 12 and 16 weeks vs SOF + RBV for 16 and 24 weeks for the treatment of genotype 3 HCV infected cirrhotic patients from the Italian National Health Service (NHS) perspective. A published cohort-based Markov model was used to perform the analysis estimating the lifetime direct medical costs associated with the management of the pathology and the quality adjusted life years gained by patients...
December 22, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27990594/health-care-costs-of-borderline-personality-disorder-and-matched-controls-with-major-depressive-disorder-a-comparative-study-based-on-anonymized-claims-data
#16
Katharina Bode, Rolf Vogel, Jochen Walker, Christoph Kröger
BACKGROUND: Borderline personality disorder (BPD) and major depressive disorder (MDD) pose a significant burden to the German health care system in terms of direct and indirect costs. The aim of this study was to determine the incremental costs that arise due to the treatment of patients with BPD, in relation to MDD patients adjusted for gender and age. METHODS: Insured persons who suffered from BPD (F60.3; N = 6599) or MDD (F32, F33; N = 26,396) in the year 2010 were identified from the German Health Risk Institute research database...
December 18, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27942967/preferences-for-public-involvement-in-health-service-decisions-a-comparison-between-best-worst-scaling-and-trio-wise-stated-preference-elicitation-techniques
#17
Seda Erdem, Danny Campbell
Stated preference elicitation techniques, such as discrete choice experiments and best-worst scaling, are now widely used in health research to explore the public's choices and preferences. In this paper, we propose an alternative stated preference elicitation technique, which we refer to as 'trio-wise'. We explain this new technique, its relative advantages, modeling framework, and how it compares to the best-worst scaling method. To better illustrate the differences and similarities, we utilize best-worst scaling Case 2, where individuals make best and worst (most and least) choices for the attribute levels that describe a single profile...
December 10, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27942966/improving-risk-equalization-with-constrained-regression
#18
Richard C van Kleef, Thomas G McGuire, René C J A van Vliet, Wynand P P M van de Ven
State-of-the-art risk equalization models undercompensate some risk groups and overcompensate others, leaving systematic incentives for risk selection. A natural approach to reducing the under- or overcompensation for a particular group is enriching the risk equalization model with risk adjustor variables that indicate membership in that group. For some groups, however, appropriate risk adjustor variables may not (yet) be available. For these situations, this paper proposes an alternative approach to reducing under- or overcompensation: constraining the estimated coefficients of the risk equalization model such that the under- or overcompensation for a group of interest equals a fixed amount...
December 10, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27942986/determinants-of-utilisation-differences-for-cancer-medicines-in-belgium-scotland-and-sweden
#19
Alessandra Ferrario
BACKGROUND: Little comparative evidence is available on utilisation of cancer medicines in different countries and its determinants. The aim of this study was to develop a statistical model to test the correlation between utilisation and possible determinants in selected European countries. METHODS: A sample of 31 medicines for cancer treatment that obtained EU-wide marketing authorisation between 2000 and 2012 was selected. Annual data on medicines' utilisation covering the in- and out-patient public sectors were obtained from national authorities between 2008 and 2013...
December 9, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
https://www.readbyqxmd.com/read/27928744/on-vaccination-programs-in-the-eu-member-states-the-case-of-the-human-papilloma-virus
#20
EDITORIAL
Reyes Lorente, Fernando Antonanzas
No abstract text is available yet for this article.
December 7, 2016: European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care
journal
journal
39984
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"